希格生科完成8000万元A轮融资 加速“类器官+AI”的全球开发

Core Insights - Hige Biotechnology (Shenzhen) Co., Ltd. has completed a Series A financing round of 80 million RMB, led by multiple investors including Jingtai Technology and Songhe Capital [1] - The funds will primarily be used to advance the global Phase II clinical trial of the company's lead pipeline SIGX1094 and the IND application and Phase I clinical trial of the second pipeline SIGX2649, focusing on targeted therapies for metastatic solid tumors [1] - Hige Biotechnology was established in 2020, utilizing an innovative "organoid + AI" drug development platform to address significant unmet clinical needs in cancers such as gastric cancer, liver cancer, and lung cancer [1] Company Pipeline - The company has four first-in-class drug pipelines and an organoid platform, with SIGX1094 being the world's first targeted drug for metastatic gastric cancer, having received clinical trial approvals in both the U.S. and China, along with orphan drug designation and fast track designation from the U.S. [2] - SIGX1094 is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and is the first drug pipeline to reach clinical stages through the "organoid + AI" technology platform [2] - The second pipeline, SIGX2649, is a pan-TEAD inhibitor targeting a key downstream effector of the Hippo signaling pathway, with no marketed drugs currently available for this target, and is set to apply for clinical trials simultaneously in the U.S. and China [2]